• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Blueprint Medicines Appoints Daniella Beckman to its Board of Directors

    12/9/21 4:01:00 PM ET
    $BPMC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPMC alert in real time by email

    CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is currently the Chief Financial Officer of Tango Therapeutics and board member for Vor Biopharma and 5:01 Acquisition Corp, brings more than 20 years of corporate strategy, finance and business operations experience.

    Print

    "Daniella's wealth of experience in the biopharmaceutical sector brings new strength to our Board of Directors," said Jeff Albers, Chief Executive Officer and Chairman of the Board of Directors of Blueprint Medicines. "We welcome her perspective and expertise as we continue our evolution as a global leader in precision therapy."

    "Blueprint Medicines has achieved impressive business results and impact for patients in its first 10 years, with two approved medicines, a broad pipeline and a fully integrated global business," said Ms. Beckman. "I'm excited to join the company at the precipice of its next wave of growth, and I look forward to working with management and other board members to realize the promise of precision medicine for even more patients with significant medical needs."

    Ms. Beckman joins Blueprint Medicines with deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Ms. Beckman oversees finance, investor relations, and business development. Prior to joining Tango, Ms. Beckman was a consultant to early-stage biotechnology companies, leading financial activities and building companies' financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, where she was responsible for finance, investor relations, and IT until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers (PwC). Ms. Beckman received her BA in business administration and accounting from Boston University. Ms. Beckman also serves as Chair of the Audit Committee and member of the Compensation Committee for the Board of Directors of Vor Biopharma, Chair of the Audit Committee and member of the Nomination and Governance Committee for the Board of Directors of 5:01 Acquisition Corp, and previously served as Chair of both the Audit and the Nomination and Governance Committees for the Board of Directors of Translate Bio.

    About Blueprint Medicines 

    Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn. 

    Cautionary Note Regarding Forward-Looking Statements 

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates, including timelines for marketing applications and approvals, the initiation of clinical trials or the results of ongoing and planned clinical trials; Blueprint Medicines' plans, strategies and timelines to nominate development candidates; plans and timelines for additional marketing applications for avapritinib and pralsetinib and, if approved, commercializing avapritinib and pralsetinib in additional geographies or for additional indications; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; the potential benefits of Blueprint Medicines' collaborations; timelines and expectations for the proposed acquisition (including future performance and revenue); and Blueprint Medicines' strategy, goals and anticipated financial performance, milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in continuing to establish and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines' ability to complete the proposed acquisition in a timely manner or at all; the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed acquisition; and the success of Blueprint Medicines' current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-daniella-beckman-to-its-board-of-directors-301441703.html

    SOURCE Blueprint Medicines Corporation

    Get the next $BPMC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BPMC

    DatePrice TargetRatingAnalyst
    6/2/2025$129.00Outperform → Neutral
    Wedbush
    3/20/2025$100.00Equal-Weight
    Morgan Stanley
    3/18/2025Outperform
    Wolfe Research
    3/17/2025$135.00Buy
    Jefferies
    3/7/2025$150.00Sector Outperform
    Scotiabank
    11/14/2024$126.00Overweight
    JP Morgan
    10/24/2024$88.00Neutral
    UBS
    5/14/2024$140.00Overweight
    Stephens
    More analyst ratings

    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Rossi Christina sold $150,309 worth of shares (1,172 units at $128.25), decreasing direct ownership by 2% to 63,546 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      7/8/25 4:20:07 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Carter Percy H. sold $134,791 worth of shares (1,051 units at $128.25), decreasing direct ownership by 2% to 53,155 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      7/8/25 4:20:05 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Albers Jeffrey W. was granted 3,902 shares, increasing direct ownership by 3% to 150,532 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      6/24/25 4:28:02 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

      -- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®/AYVAKYT® (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses

      6/12/25 6:01:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    SEC Filings

    See more
    • Amendment: SEC Form SC 14D9/A filed by Blueprint Medicines Corporation

      SC 14D9/A - Blueprint Medicines Corp (0001597264) (Subject)

      7/10/25 6:18:19 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Blueprint Medicines Corporation

      SC TO-T/A - Blueprint Medicines Corp (0001597264) (Subject)

      7/10/25 6:04:59 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Blueprint Medicines Corp (0001597264) (Filer)

      6/20/25 8:04:49 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Blueprint Medicines downgraded by Wedbush with a new price target

      Wedbush downgraded Blueprint Medicines from Outperform to Neutral and set a new price target of $129.00

      6/2/25 8:41:53 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Blueprint Medicines with a new price target

      Morgan Stanley resumed coverage of Blueprint Medicines with a rating of Equal-Weight and set a new price target of $100.00

      3/20/25 7:59:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Blueprint Medicines

      Wolfe Research initiated coverage of Blueprint Medicines with a rating of Outperform

      3/18/25 7:49:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Blueprint Medicines Corporation

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      11/14/24 1:22:36 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      4/10/24 12:58:49 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      2/14/24 10:03:02 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Leadership Updates

    Live Leadership Updates

    See more
    • Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

      -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa

      11/22/22 4:36:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

      Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

      8/8/22 6:15:00 AM ET
      $BPMC
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

      -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos

      7/14/22 4:15:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Financials

    Live finance-specific insights

    See more
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care